MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea · Delayed Price · Currency is KRW

590.00

-31.00 (-4.99%)

At close: Jun 19, 2026

-72.49% (1Y)

Market Cap	24.88B -51.6%
Revenue (ttm)	10.45B -24.2%
Net Income	-12.86B
EPS	-340.35
Shares Out	42.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,208
Open	616.00
Previous Close	621.00
Day's Range	580.00 - 646.00
52-Week Range	550.00 - 2,230.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 42

Stock Exchange KOSDAQ

Ticker Symbol 142760

Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements